Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Salona Global Medical Device ( (TSE:EVMT) ) just unveiled an announcement.
Evome Medical Technologies is facing several operational challenges, including rising input costs due to potential tariffs, the exit of its asset-based loan provider, and a lack of funds for its year-end audit. The company has appointed a new management team to navigate these issues, with Chris Heath stepping in as Interim CEO. Despite these hurdles, Evome continues to fulfill customer orders and is actively marketing its DaMar unit for sale. The company is committed to maintaining product deliveries while adjusting to current financial constraints.
More about Salona Global Medical Device
Evome Medical Technologies Inc. operates in the medical device industry, generating revenue through three main lines: DaMar, a contract manufacturing business in California; Biodex, a branded medical device business with a significant international presence; and The Tables Business, a specialized contract manufacturing unit within Biodex.
YTD Price Performance: -39.29%
Average Trading Volume: 79,492
Technical Sentiment Signal: Buy
Current Market Cap: C$7.06M
For an in-depth examination of EVMT stock, go to TipRanks’ Stock Analysis page.